Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Op-T-Mune Inc
Profile last edited on: 3/25/19      CAGE: 67BC      UEI: K2XFYLHNXPY3

Business Identifier: Developing treatments and diagnostics for autoimmune disease
Year Founded
2008
First Award
2012
Latest Award
2020
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

3000 East 7th Avenue Parkway
Denver, CO 80206
   (303) 929-7865
   N/A
   N/A
Location: Single
Congr. District: 01
County: Denver

Public Profile

Op-T-Mune was founded to commercialize the intellectual property of Dr. David Wagner, Associate Professor at the University of Colorado Denver. Dr. Wagner has developed a means to control autoimmune inflammation, specifically in type 1 diabetes and multiple sclerosis (MS). In addition, Dr. Wagner has developed a means to identify the pathogenic cells in those diseases that is being developed as a diagnostic tool.

Extent of SBIR involvement

User Avatar
Phase I Awards
5
Phase II Awards
2
Conversion Rate
40.00%
Phase I Dollars
$1,529,379
Phase II Dollars
$2,919,787
Total Awarded
$4,449,166

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2020 2 NIH $2,061,888
Project Title: Developing a Small Peptide to Control Autoimmune Inflammation in Type 1 Diabetes
2019 2 NIH $1,576,468
Project Title: Development of a Clinical Screening Platform for Type 1 Diabetes
2017 1 NIH $299,002
Project Title: Screening for the autoimmune component of multiple sclerosis
2014 1 NIH $211,808
Project Title: Developing a New Treatment for MS: Controlling CD40 in EAE
2012 1 NIH $300,000
Project Title: Screening For Type 1 Diabetes: A Blood Test Based On The Cd40 Biomarker

Key People / Management

  Cecil Del

  Peter Nelson

  David H Wagner -- Chief Scientific Officer

Company News

There are no news available.